Stroke treatment - light at the end of the tunnel?

Article Abstract:

Biotechnology firms are moving ahead with new approaches and treatments for ischemic stroke despite the high-profile failures of many stroke drugs in late-stage clinical trials. Firms are pursuing new fibrinolytics to restore blood flow, drugs to protect brain cells from stroke damage and agents to help the brain's natural recovery mechanisms.

Product development, Science & research, Blood Clot Dissolvers, Care and treatment, Research, Pharmaceutical industry, Stroke (Disease), Stroke, Fibrinolytic agents, Thrombolytic drugs

---

rFactor VIII deficit questioned

Article Abstract:

The National Hemophilia Foundation questions that there is really a shortage of recombinant factor VIII. Some feel that Leverkusen, Germany-based has used the supposed shortage to drive fearful patients into its new, controversial direct purchase program.

Germany, Production data, Bayer AG, BAYZY

---

Protein C may be sepsis solution

Article Abstract:

Indianapolis, IN-based Eli Lilly plans to submit a biological license application at the beginning of 2001 for its sepsis drug Zovant, recombinant activated protein C. The company will petition the FDA for expedited review.

Product introduction, Public affairs, Systemic Antibiotic Preparations, Antibiotics

Similar abstracts:

• Abstracts: Ten reasons to turn to the web. The online share dealing revolution. Revealed: UK's best online brokers
• Abstracts: Solving the unit trust selector's dilemma. Henderson Eurotrust
• Abstracts: Packaged deals. Tricks of the trade,
• Abstracts: Investors left counting the cost of Crest. On the Crest of lower charges. Web to slash self-select Isa charges
• Abstracts: Investing in the future. Division: a new dawn. Delcam

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.